[{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"ALS Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Funding","leadProduct":"ORY-4001","moa":"HDAC-6","graph1":"Neurology","graph2":"Preclinical","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oryzon Genomics \/ ALS Association","highestDevelopmentStatusID":"4","companyTruncated":"Oryzon Genomics \/ ALS Association"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ORY-4001","moa":"HDAC-6","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Med4Cure","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2025","type":"Funding","leadProduct":"Iadademstat","moa":"LSD1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Med4Cure","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Med4Cure"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Iadademstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"European Commission","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Funding","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oryzon Genomics \/ European Commission","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ European Commission"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Iadademstat","moa":"LSD1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"European Commission","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Funding","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oryzon Genomics \/ European Commission","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ European Commission"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oryzon Genomics \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ National Cancer Institute"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase I","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Iadademstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Eurostars","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Funding","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oryzon Genomics \/ Eurostars","highestDevelopmentStatusID":"1","companyTruncated":"Oryzon Genomics \/ Eurostars"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Oryzon Genomics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Iadademstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oryzon Genomics \/ Oryzon Genomics","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Oryzon Genomics"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Neurology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Neurology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Kennedy Krieger Institute","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Kennedy Krieger Institute","highestDevelopmentStatusID":"7","companyTruncated":"Oryzon Genomics \/ Kennedy Krieger Institute"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Nice & Green","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Financing","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.050000000000000003,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Nice & Green","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Nice & Green"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Neurology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Spanish Ministry Of Science and Innovation","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Spanish Ministry Of Science and Innovation","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Spanish Ministry Of Science and Innovation"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Vall d\u2019Hebron Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Vall d\u2019Hebron Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Vall d\u2019Hebron Hospital"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Maxim","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2025","type":"Financing","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Maxim","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Maxim"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Kabuki Syndrome Foundation","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Funding","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Kabuki Syndrome Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Oryzon Genomics \/ Kabuki Syndrome Foundation"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Columbia University","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Oryzon Genomics","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Oryzon Genomics"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"CMT Research Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oryzon Genomics \/ CMT Research Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Oryzon Genomics \/ CMT Research Foundation"}]

Find Clinical Drug Pipeline Developments & Deals by Oryzon Genomics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : The proceeds will be used to accelerate the next steps in the clinical development of ORY-2001 (vafidemstat), an oral, CNS-optimized LSD1 inhibitor, for the treatment of CNS disorders.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          May 08, 2025

                          Lead Product(s) : Iadademstat

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Med4Cure

                          Deal Size : $15.0 million

                          Deal Type : Funding

                          blank

                          02

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : The funds raised will be used to advance the clinical development of ORY-2001 (vafidemstat) for the treatment of aggression in CNS disorders such as BPD and Autism Spectrum Disorder.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          April 24, 2025

                          Lead Product(s) : Vafidemstat

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Maxim

                          Deal Size : $34.0 million

                          Deal Type : Financing

                          blank

                          03

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : ORY-1001 (iadademstat) is a highly selective inhibitor of the epigenetic enzyme LSD1. It is being investigated in patients with extensive-stage small cell lung cancer.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 15, 2025

                          Lead Product(s) : Iadademstat,Atezolizumab,Durvalumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : ORY-2001 (vafidemstat) is an oral, CNS-optimized LSD1 inhibitor. It is under phase 2 clinical development for the treatment of Borderline Personality Disorder (BPD).

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 03, 2025

                          Lead Product(s) : Vafidemstat

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : ORY-1001 (iadademstat) is a highly selective inhibitor of the epigenetic enzyme LSD1. It is being investigated in patients with myelodysplastic syndrome.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 23, 2025

                          Lead Product(s) : Iadademstat,Azacitidine,Venetoclax

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : ORY-1001 (iadademstat) is a highly selective inhibitor of the epigenetic enzyme LSD1. It is being investigated in combination with venetoclax & azacitidine in patients with acute myeloid leukemia.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 13, 2025

                          Lead Product(s) : Iadademstat,Azacitidine,Venetoclax

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : ORY-2001 (vafidemstat) is an oral, CNS-optimized LSD1 inhibitor. It is under phase 2 clinical development for the treatment of Borderline Personality Disorder (BPD).

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 01, 2024

                          Lead Product(s) : Vafidemstat

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : ORY-1001 (iadademstat) is a highly selective inhibitor of the epigenetic enzyme LSD1. It is being investigated in combination with venetoclax & azacitidine in patients with acute myeloid leukemia.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 09, 2024

                          Lead Product(s) : Iadademstat,Azacitidine,Venetoclax

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : ORY-1001 (iadademstat) is a selective LSD1 inhibitor investigated with immune checkpoint inhibitors in extensive disease small cell lung cancer patients.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 08, 2024

                          Lead Product(s) : Iadademstat,Durvalumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : ORY-2001 (vafidemstat) is an oral, CNS-optimized LSD1 inhibitor. It is under phase 2 clinical development for the treatment of Borderline Personality Disorder (BPD).

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 05, 2023

                          Lead Product(s) : Vafidemstat

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank